Portola Pharmaceuticals is an American clinical stage biotechnology company that researches, develops, and commercializes drugs.
The company focuses primarily on drugs used in the treatment of thrombosis and hematological malignancies.
[2] Founded in 2003 and headquartered in South San Francisco, California, Portola Pharmaceuticals is a member of the NASDAQ Biotechnology Index.
[3] The company was founded on September 2, 2003,[4] and named after Gaspar de Portolà, who was the first European to see San Francisco Bay.
[7] In the class action lawsuit of Hayden v. Portola Pharmaceuticals in U.S. District Court, in the Northern District of California, before U.S. District Judge Vince Chhabria, plaintiffs sued under Section 11 of the Securities Act of 1933 alleging that the company and its underwriters misrepresented its financial position ahead of a 2019 securities offering.